Therapies involving immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have demonstrated significant improvements in the overall survival (OS) of patients with advanced non-small cell lung cancer (NSCLC) (1–4). Here, PDCD1 is linked to non-small cell lung carcinoma.